Thiocolchicoside suppresses osteoclastogenesis induced by RANKL and cancer cells through inhibition of inflammatory pathways: A new use for an old drug

British Journal of Pharmacology

Volumn 165, Issue 7, 2012, Pages 2127-2139

  Reuter, Simone ^a   Gupta, Subash C ^a   Phromnoi, Kanokkarn ^a   Aggarwal, Bharat B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

cancer; NF B; osteoclastogenesis; RANKL; thiocolchicoside

Indexed keywords

I KAPPA B KINASE ALPHA; I KAPPA B KINASE GAMMA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; THIOCOLCHICOSIDE;

ANIMAL CELL; ARTICLE; BONE DISEASE; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; DRUG EFFICACY; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME REPRESSION; MOUSE; MYALGIA; NONHUMAN; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANIMALS; BONE NEOPLASMS; BONE RESORPTION; CELL LINE; COLCHICINE; ENZYME ACTIVATION; FEMALE; HUMANS; I-KAPPA B KINASE; INFLAMMATION; LILIACEAE; MALE; MICE; NF-KAPPA B; OSTEOCLASTS; PHYTOTHERAPY; RANK LIGAND; SIGNAL TRANSDUCTION;

EID: 84863229968     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01702.x     Document Type: Article

References (58)

1. Abu-Amer Y, Dowdy SF, Ross FP, Clohisy JC, Teitelbaum SL, (2001). TAT fusion proteins containing tyrosine 42-deleted IkappaBalpha arrest osteoclastogenesis. J Biol Chem 276: 30499-30503.
2. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, et al,. (1997). A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390: 175-179. (Pubitemid 27507987)
3. Bauer DC, Orwoll ES, Fox KM, Vogt TM, Lane NE, Hochberg MC, et al,. (1996). Aspirin and NSAID use in older women: effect on bone mineral density and fracture risk. Study of Osteoporotic Fractures Research Group. J Bone Miner Res 11: 29-35. (Pubitemid 26026741)
4. Bharti AC, Aggarwal BB, (2004). Ranking the role of RANK ligand in apoptosis. Apoptosis 9: 677-690. (Pubitemid 40941197)
5. Bharti AC, Shishodia S, Reuben JM, Weber D, Alexanian R, Raj-Vadhan S, et al,. (2004a). Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 103: 3175-3184. (Pubitemid 38451696)
6. Bharti AC, Takada Y, Aggarwal BB, (2004b). Curcumin (diferuloylmethane) inhibits receptor activator of NF-kappa B ligand-induced NF-kappa B activation in osteoclast precursors and suppresses osteoclastogenesis. J Immunol 172: 5940-5947. (Pubitemid 38621193)
7. Bhatia P, Sanders MM, Hansen MF, (2005). Expression of receptor activator of nuclear factor-kappaB is inversely correlated with metastatic phenotype in breast carcinoma. Clin Cancer Res 11: 162-165. (Pubitemid 40075791)
8. Biswas DK, Shi Q, Baily S, Strickland I, Ghosh S, Pardee AB, et al,. (2004). NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci U S A 101: 10137-10142. (Pubitemid 38891208)
9. Biziere K, Huguet F, Narcisse G, Breteau M, (1981). Affinity of thiocolchicoside and thiocolchicoside analogues for the postsynaptic GABA receptor site. Eur J Pharmacol 75: 167-168. (Pubitemid 11026502)
10. Body JJ, Facon T, Coleman RE, Lipton A, Geurs F, Fan M, et al,. (2006). A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 12: 1221-1228. (Pubitemid 43342512)
11. Boyle WJ, Simonet WS, Lacey DL, (2003). Osteoclast differentiation and activation. Nature 423: 337-342. (Pubitemid 40852708)
12. Canon JR, Roudier M, Bryant R, Morony S, Stolina M, Kostenuik PJ, et al,. (2008). Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis 25: 119-129.
13. Chaisson ML, Branstetter DG, Derry JM, Armstrong AP, Tometsko ME, Takeda K, et al,. (2004). Osteoclast differentiation is impaired in the absence of inhibitor of kappa B kinase alpha. J Biol Chem 279: 54841-54848. (Pubitemid 40053230)
14. Cimino M, Marini P, Cattabeni F, (1996). Interaction of thiocolchicoside with [3H]strychnine binding sites in rat spinal cord and brainstem. Eur J Pharmacol 318: 201-204. (Pubitemid 27033224)
15. Clohisy JC, Roy BC, Biondo C, Frazier E, Willis D, Teitelbaum SL, et al,. (2003). Direct inhibition of NF-kappa B blocks bone erosion associated with inflammatory arthritis. J Immunol 171: 5547-5553. (Pubitemid 37432845)
16. Coleman RE, (2001). Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27: 165-176. (Pubitemid 32452017)
17. Coleman RE, (2006). Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12: 6243s-6249s. (Pubitemid 44703797)
18. Dai S, Hirayama T, Abbas S, Abu-Amer Y, (2004). The IkappaB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis. J Biol Chem 279: 37219-37222. (Pubitemid 39195425)
19. Drake MT, Clarke BL, Khosla S, (2008). Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 83: 1032-1045.
20. Farrugia AN, Atkins GJ, To LB, Pan B, Horvath N, Kostakis P, et al,. (2003). Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res 63: 5438-5445. (Pubitemid 37139862)
21. Franzoso G, Carlson L, Xing L, Poljak L, Shores EW, Brown KD, et al,. (1997). Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev 11: 3482-3496. (Pubitemid 28023969)
22. Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barille S, (2001). Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 98: 3527-3533.
23. Giuliani N, Colla S, Sala R, Moroni M, Lazzaretti M, La Monica S, et al,. (2002). Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood 100: 4615-4621. (Pubitemid 35429706)
24. Han SY, Lee NK, Kim KH, Jang IW, Yim M, Kim JH, et al,. (2005). Transcriptional induction of cyclooxygenase-2 in osteoclast precursors is involved in RANKL-induced osteoclastogenesis. Blood 106: 1240-1245. (Pubitemid 41129585)
25. Heider U, Langelotz C, Jakob C, Zavrski I, Fleissner C, Eucker J, et al,. (2003). Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. Clin Cancer Res 9: 1436-1440. (Pubitemid 36418398)
26. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, et al,. (1999). Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 96: 3540-3545. (Pubitemid 29168945)
27. Janbroers JM, (1987). Review of the toxicology, pharmacodynamics and pharmacokinetics of thiocolchicoside, a GABA-agonist muscle relaxant with anti-inflammatory and analgesic actions. Acta Ther 13: 221-250. (Pubitemid 17057153)
28. Jimenez-Andrade JM, Mantyh WG, Bloom AP, Ferng AS, Geffre CP, Mantyh PW, (2010). Bone cancer pain. Ann N Y Acad Sci 1198: 173-181.
29. Kasukawa Y, Miyakoshi N, Srivastava AK, Nozaka K, Maekawa S, Baylink DJ, et al,. (2007). The selective cyclooxygenase-2 inhibitor celecoxib reduces bone resorption, but not bone formation, in ovariectomized mice in vivo. Tohoku J Exp Med 211: 275-283. (Pubitemid 46488384)
30. Ketenci A, Ozcan E, Karamursel S, (2005). Assessment of efficacy and psychomotor performances of thiocolchicoside and tizanidine in patients with acute low back pain. Int J Clin Pract 59: 764-770. (Pubitemid 43904540)
31. Ketenci A, Basat H, Esmaeilzadeh S, (2009). The efficacy of topical thiocolchicoside (Muscoril) in the treatment of acute cervical myofascial pain syndrome: a single-blind, randomized, prospective, phase IV clinical study. Agri 21: 95-103.
32. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, et al,. (1999). OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397: 315-323.
33. Kopp E, Ghosh S, (1994). Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 265: 956-959.
34. Kunnumakkara AB, Nair AS, Ahn KS, Pandey MK, Yi Z, Liu M, et al,. (2007). Gossypin, a pentahydroxy glucosyl flavone, inhibits the transforming growth factor beta-activated kinase-1-mediated NF-kappaB activation pathway, leading to potentiation of apoptosis, suppression of invasion, and abrogation of osteoclastogenesis. Blood 109: 5112-5121. (Pubitemid 46890525)
35. Kyle RA, Yee GC, Somerfield MR, Flynn PJ, Halabi S, Jagannath S, et al,. (2007). American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 25: 2464-2472. (Pubitemid 46999218)
36. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al,. (1998). Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165-176. (Pubitemid 28180851)
37. Lai FP, Cole-Sinclair M, Cheng WJ, Quinn JM, Gillespie MT, Sentry JW, et al,. (2004). Myeloma cells can directly contribute to the pool of RANKL in bone bypassing the classic stromal and osteoblast pathway of osteoclast stimulation. Br J Haematol 126: 192-201. (Pubitemid 38961937)
38. Miyazaki T, Katagiri H, Kanegae Y, Takayanagi H, Sawada Y, Yamamoto A, et al,. (2000). Reciprocal role of ERK and NF-kappaB pathways in survival and activation of osteoclasts. J Cell Biol 148: 333-342. (Pubitemid 30078245)
39. Neville-Webbe HL, Coleman RE, (2010). Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease. Eur J Cancer 46: 1211-1222.
40. Pandey MK, Sandur SK, Sung B, Sethi G, Kunnumakkara AB, Aggarwal BB, (2007). Butein, a tetrahydroxychalcone, inhibits nuclear factor (NF)-kappaB and NF-kappaB-regulated gene expression through direct inhibition of IkappaBalpha kinase beta on cysteine 179 residue. J Biol Chem 282: 17340-17350. (Pubitemid 47100316)
41. Pearse RN, Sordillo EM, Yaccoby S, Wong BR, Liau DF, Colman N, et al,. (2001). Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A 98: 11581-11586. (Pubitemid 32928771)
42. Phan TC, Xu J, Zheng MH, (2004). Interaction between osteoblast and osteoclast: impact in bone disease. Histol Histopathol 19: 1325-1344. (Pubitemid 39386790)
43. Reuter S, Prasad S, Phromnoi K, Ravindran J, Sung B, Yadav VR, et al,. (2010). Thiocolchicoside exhibits anticancer effects through downregulation of NF-{kappa}B pathway and its regulated gene products linked to inflammation and cancer. Cancer Prev Res (Phila) 3: 1462-1472.
44. Roodman GD, (2001). Biology of osteoclast activation in cancer. J Clin Oncol 19: 3562-3571. (Pubitemid 32734171)
45. Ruocco MG, Maeda S, Park JM, Lawrence T, Hsu LC, Cao Y, et al,. (2005). I{kappa}B kinase (IKK){beta}, but not IKK{alpha}, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J Exp Med 201: 1677-1687. (Pubitemid 40721011)
46. Saad F, Markus R, Goessl C, (2008). Targeting the receptor activator of nuclear factor-kappaB (RANK) ligand in prostate cancer bone metastases. BJU Int 101: 1071-1075. (Pubitemid 351502650)
47. Soonawalla DF, Joshi N, (2008). Efficacy of thiocolchicoside in Indian patients suffering from low back pain associated with muscle spasm. J Indian Med Assoc 106: 331-335.
48. Sung B, Pandey MK, Aggarwal BB, (2007). Fisetin, an inhibitor of cyclin-dependent kinase 6, down-regulates nuclear factor-kappaB-regulated cell proliferation, antiapoptotic and metastatic gene products through the suppression of TAK-1 and receptor-interacting protein-regulated IkappaBalpha kinase activation. Mol Pharmacol 71: 1703-1714. (Pubitemid 47010923)
49. Sung B, Murakami A, Oyajobi BO, Aggarwal BB, (2009). Zerumbone abolishes RANKL-induced NF-kappaB activation, inhibits osteoclastogenesis, and suppresses human breast cancer-induced bone loss in athymic nude mice. Cancer Res 69: 1477-1484.
50. Sung B, Cho SG, Liu M, Aggarwal BB, (2011). Butein, a tetrahydroxychalcone, suppresses cancer-induced osteoclastogenesis through inhibition of RANKL signaling. Int J Cancer 129: 2062-2072.
51. Takahashi N, Udagawa N, Tanaka S, Murakami H, Owan I, Tamura T, et al,. (1994). Postmitotic osteoclast precursors are mononuclear cells which express macrophage-associated phenotypes. Dev Biol 163: 212-221. (Pubitemid 24188885)
52. Teitelbaum SL, (2000). Bone resorption by osteoclasts. Science 289: 1504-1508.
53. Terpos E, Rahemtulla A, (2004). Bisphosphonate treatment for multiple myeloma. Drugs Today (Barc) 40: 29-40. (Pubitemid 38270553)
54. Tuzun F, Unalan H, Oner N, Ozguzel H, Kirazli Y, Icagasioglu A, et al,. (2003). Multicenter, randomized, double-blinded, placebo-controlled trial of thiocolchicoside in acute low back pain. Joint Bone Spine 70: 356-361. (Pubitemid 37243271)
55. Wei S, Teitelbaum SL, Wang MW, Ross FP, (2001). Receptor activator of nuclear factor-kappa b ligand activates nuclear factor-kappa b in osteoclast precursors. Endocrinology 142: 1290-1295. (Pubitemid 32202841)
56. Xu J, Wu HF, Ang ES, Yip K, Woloszyn M, Zheng MH, et al,. (2009). NF-kappaB modulators in osteolytic bone diseases. Cytokine Growth Factor Rev 20: 7-17.
57. Yavropoulou MP, Yovos JG, (2008). Osteoclastogenesis-current knowledge and future perspectives. J Musculoskelet Neuronal Interact 8: 204-216.
58. Zheng H, Yu X, Collin-Osdoby P, Osdoby P, (2006). RANKL stimulates inducible nitric-oxide synthase expression and nitric oxide production in developing osteoclasts. An autocrine negative feedback mechanism triggered by RANKL-induced interferon-beta via NF-kappaB that restrains osteoclastogenesis and bone resorption. J Biol Chem 281: 15809-15820. (Pubitemid 43848471)